Integrative predictive modelling and multi-omics validation reveals potential indicators of clinical heterogeneity in HCC.
BACKGROUND The escalating incidence and mortality rates of hepatocellular carcinoma (HCC), coupled with delayed diagnosis, resistance to existing therapies, and profound molecular heterogeneity, underscore the urgent need for improved, clinically actionable biomarkers. METHODS Large-scale transcriptomic datasets were...